• Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to primary sidebar
  • Skip to footer

Action Duchenne

Gene therapy

Duchenne muscular dystrophy is caused by mutations in the dystrophin gene that prevent the body producing the dystrophin protein. The idea behind gene therapy is simple: to add a second, healthy copy of the dystrophin gene, which cells can use to produce the dystrophin protein.

Using viruses to deliver a gene

Current trials are using viruses to deliver the gene therapy. Researchers remove the virus’ own DNA and insert the DNA code for dystrophin. The virus can then deliver this code to the cells.

Although different viruses have been tested in gene therapies, all the ongoing clinical trials focus on a type of virus called adeno-associated viruses (or AAV).

AAV are viruses that infect humans all the time, but they cause very minor symptoms. Often people wouldn’t even realise they are infected. This makes the virus a good choice for clincial use.

The viruses chosen for use in Duchenne are those that naturally infect the muscle cells – this is an important part of getting the gene where it is most needed.

What gene do the viruses carry?

The dystrophin gene is incredibly big – the biggest in human cells. The gene is too big to physically fit inside an AAV; there just isn’t enough space. It’s not possible to make the virus bigger, so scientists have developed smaller version of the dystrophin gene.

These are called micro-dystrophin genes.

Nobody is quite sure which micro-dystrophin would be most effective in people living with Duchenne, so different micro-dystrophin genes are being tested in different clinical trials by different companies and groups.

What are the challenges?

There are several challenges to overcome.

Firstly, nobody knows how long the micro-dystrophin gene will last in the body. As cells grow and divide, the gene will be “diluted” and eventually it’s effectiveness will be lost.

Some people will be immune to AAVs because they have been infected naturally. This immunity would prevent the gene therapy virus reaching the muscle cells and make the treatment ineffective. Immunity is also likely to prevent people receiing a second dose of gene therapy – because the immune system will “remember” the gene therapy virus used before.

Gene therapy news

Read the latest news on how gene therapy is being developed for Duchenne

Read more

Gene therapy glossary

Watch our short videos that explain how gene therapy works and the promising results observed in clinical trials

Read more

Our gene therapy research

Find out more about the UNITE-DMD gene therapy clinical trial that we are co-funding

Read more
Share this:

Primary Sidebar

From our community

The Heart of Care

The Heart of Care We have had some key reminders of what we are working towards as a charity over the last few weeks. Volunteer’s Week (2nd – 8th June) was a chance to thank all of the people who give up their time and expertise for Action Duchenne. From the team of trustees, those …

Mental Health Awareness Week: Alex’s Journal

Written By Alex Berbank 15 Minutes a Day I’ve really enjoyed getting into the frame of mind to look at my mental health. Before this week I wasn’t quite sure what to expect. My ideas of what looking at my own mental health would look like weren’t accurate. I thought there would be more softly …

Mental Health Awareness Week: Alex’s Journal

Mental Health Awareness Week Journal, Written by Alex Berbank Watch Alex’s Vlog for Mental Health Awareness Week Thursday’s Update: Meditation and Mindfulness So, to this point this week has been great. I’ve actually taken to the focus on my mental health and self improvement thing quite well and I hope I’ll keep these new ideas …

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852

Like most websites we use cookies to deliver a personalised service. To use the website as intended please accept cookies.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT